Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial

Beni-Suef University Journal of Basic and Applied Sciences

Table 2 Clinical outcomes in both groups after 12-week therapy compared by baseline

Parameters	Sitagliptin (n = 82)	p-Value	Empagliflozin (n = 75)	p-Value	p-Value after comparing both groups
HbA1c (%)
Mean ± SD	8.272 ± 1.9169	0.293	7.177 ± 1.3182	< 0.001	< 0.001
FBG (mg/dl)
Mean ± SD	155.305 ± 59.4488	0.001	131.693 ± 43.2938	< 0.001	0.005
PP (mg/dl)
Mean ± SD	225.012 ± 87.0772	0.001	178.173 ± 66.9137	< 0.001	< 0.001
LDL (mg/dl)
Mean ± SD	121.646 ± 29.6937	0.377	143.960 ± 25.3428	< 0.001	< 0.001
Total cholesterol (mg/dl)
Mean ± SD	194.841 ± 42.3581	0.109	220.573 ± 33.0410	0.001	< 0.001
HDL (mg/dl)
Mean ± SD	49.061 ± 9.3800	< 0.001	48.680 ± 8.3004	< 0.001	0.788
TG (mg/dl)
Mean ± SD	165.866 ± 60.9488	< 0.001	147.947 ± 52.1067	< 0.001	0.049
SBP (mmHg)
Mean ± SD	128.951 ± 17.4150	0.009	132.067 ± 12.9211	0.016	0.203
DBP (mmHg)
Mean ± SD	80.463 ± 6.2226	0.074	82.867 ± 8.3494	0.006	0.041
Body weight (kg)
Mean ± SD	89.807 ± 15.4907	< 0.001	91.907 ± 18.0076	0.001	0.437